News &amp; Updates

Use of misoprostol can effectively mend small bowel injuries (SBI) caused by NSAIDs or aspirin, reports a recent study.

Vonoprazan on par with PPIs in BCQ therapy for H. pylori eradication

Vonoprazan-based bismuth-containing quadruple therapy (VBCQ) does better at eradicating Helicobacter pylori (H. pylori) than proton pump inhibitor (PPI)-based BCQ therapy (PBCQ), with similar adverse reactions and compliance, a study has shown.

08 Nov 2024

Aumolertinib ups PFS in EGFR-mutated NSCLC

08 Nov 2024 by

Treatment with aumolertinib significantly prolonged progression-free survival (PFS) compared with placebo in patients with unresectable stage III EGFR-mutated non-small cell lung cancer (NSCLC) who did not experience disease progression following chemoradiotherapy (CRT), according to a preplanned interim analysis of the phase III POLESTAR trial presented at WCLC 2024.

Menopausal hormone therapy prevents relapse in women with SSD

Use of menopausal hormone therapy (MHT) can avert psychosis relapse in women with schizophrenia or schizoaffective disorder (SSD) of menopausal age, suggests a recent study.

07 Nov 2024

Lomitapide lowers LDL-C levels in paediatric homozygous familial hypercholesterolaemia

Children with homozygous familial hypercholesterolaemia (HoFH) achieve significant and clinically meaningful reductions in low-density lipoprotein cholesterol (LDL-C) with the microsomal triglyceride transfer protein (MTP) inhibitor lomitapide, which represents an efficient LDL receptor-independent treatment option, according to the open-label phase III APH-19 trial.

Original New Drug Application Approvals by US FDA (16-31 October 2024)

New drug applications approved by US FDA as of 16-31 October 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Vitamin K2 supplementation eases leg cramps in seniors

06 Nov 2024 by

Daily supplementation with vitamin K2 helps minimize the frequency, intensity, and duration of nocturnal leg cramps in older adults while having a good safety profile, as shown in a study.

Is rapid-rate oxaliplatin safer than standard infusion?

Rapid infusion of oxaliplatin appears to have minimal treatment modifications relative to standard administration but may lead to a higher incidence of peripheral neuropathy (PN), according to a study.

Increased risk of inflammatory CNS diseases following anti-TNF therapy for autoimmune diseases

06 Nov 2024 by

Compared with conventional therapies, exposure to tumour necrosis factor (TNF) inhibitors is associated with increased risk of inflammatory central nervous system (CNS) diseases, irrespective of background autoimmune disease or TNF inhibitor type, a recent meta-analysis has found.